How to buy Sinopharm Group Co. (SHTDF) shares in the UK

Learn how to easily invest in Sinopharm Group Co. shares.

Sinopharm Group Co. Ltd (SHTDF) is a publicly traded medical distribution business based in China. On 20 September Sinopharm Group Co. shares plunged 9.00% to a closing position of $1.92. However, over the last 12 months, Sinopharm Group Co.'s share price has risen by 11.28% from $2.615. Sinopharm Group Co. is listed on the PINK and employs 112,859 staff. All prices are listed in US Dollars.

How to buy shares in Sinopharm Group Co.

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: SHTDF in this case.
  5. Research Sinopharm Group Co. shares. The platform should provide the latest information available.
  6. Buy your Sinopharm Group Co. shares. It's that simple.
The whole process can take as little as 15 minutes. You'll need a smartphone or computer, an internet connection, your passport or driving licence and a means of payment.

Share dealing platform comparison

Table: sorted by promoted deals first
Name Product Ratings Finder rating Customer rating Min. initial deposit Price per trade Frequent trader rate Platform fee Offer Link
FREE TRADES
IG Share Dealing
Finder score
★★★★★
User survey
★★★★★
★★★★★
Expert analysis
★★★★★
User survey
£250
UK: £8
US: £10
EU: 0.1% (min €10)
UK: £3
US: £0
EU: 0.1% (min €10)
£0
Get 0% commission on US shares when you make 3+ trades in the previous month.

Capital at risk

Platform details
FREE TRADES
eToro Free Stocks
Finder score
★★★★★
User survey
★★★★★
★★★★★
Expert analysis
★★★★★
User survey
$10
£0
N/A
£0

Capital at risk

Platform details
OFFER
Fineco
Finder score
★★★★★
User survey
★★★★★
★★★★★
Expert analysis
★★★★★
User survey
£0
UK: £2.95
US: $3.95
EU: €3.95
N/A
£0
Get £500 in trading commissions to use in the first 3 months (T&Cs apply)

Capital at risk

Platform details
Hargreaves Lansdown Fund and Share Account
Finder score
★★★★★
User survey
★★★★★
★★★★★
Expert analysis
★★★★★
User survey
£1
£11.95
£5.95
£0

Capital at risk

Platform details
Degiro Share Dealing
Finder score
★★★★★
User survey
★★★★★
★★★★★
Expert analysis
★★★★★
User survey
£0.01
UK: £1.75 + 0.014% (max £5)
US: €0
N/A
£0

Capital at risk

Platform details
loading

Compare up to 4 providers

Sinopharm Group Co. share price (PINK:SHTDF)

Use our graph to track the performance of SHTDF stocks over time.

Sinopharm Group Co. price performance over time

Historical closes compared with the last close of $2.91

1 week (2022-09-22) 51.56%
1 month (2022-08-29) 32.88%
3 months (2022-06-29) 22.27%
6 months (2022-03-29) 25.43%
1 year (2021-09-29) 11.28%
2 years (2020-09-29) 36.62%
3 years (2019-09-27) -6.52%
5 years (2017-09-29) -33.10%
Promoted
eToro Free Stocks

Invest in Sinopharm Group Co. shares with 0% commission

  • Start investing from as little as $10
  • Pay no stamp duty on UK shares
  • Join 25 million users who trust their investments with eToro
Other fees apply. Capital at risk

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is Sinopharm Group Co. under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.

P/E ratio

Sinopharm Group Co.'s current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 6x. In other words, Sinopharm Group Co. shares trade at around 6x recent earnings.

PEG ratio

Sinopharm Group Co.'s "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 49.0237. Higher PEG ratios such as this can be interpreted as meaning the shares offer worse value given the current rate of growth.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sinopharm Group Co.'s future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

EBITDA

Sinopharm Group Co.'s EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $23.3 billion (£21.1 billion).

The EBITDA is a measure of a Sinopharm Group Co.'s overall financial performance and is widely used to measure a its profitability.

Environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Sinopharm Group Co..

Total ESG risk score

Sinopharm Group Co.'s total ESG risk: 22.65

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Sinopharm Group Co.'s overall score of 22.65 (as at 01/01/2019) is excellent – landing it in it in the 18th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Sinopharm Group Co. is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Environmental score

Sinopharm Group Co.'s environmental score: 9.35/100

Sinopharm Group Co.'s environmental score of 9.35 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Sinopharm Group Co. is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Social score

Sinopharm Group Co.'s social score: 9.88/100

Sinopharm Group Co.'s social score of 9.88 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that Sinopharm Group Co. is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Governance score

Sinopharm Group Co.'s governance score: 14.42/100

Sinopharm Group Co.'s governance score puts it squarely in the 8th percentile of companies rated in the same sector. That could suggest that Sinopharm Group Co. is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Controversy score

Sinopharm Group Co.'s controversy score: 1/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Sinopharm Group Co. scored a 1 out of 5 for controversy – the highest score possible, reflecting that Sinopharm Group Co. has managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Sinopharm Group Co. Ltd was last rated for ESG on: 2019-01-01.

Total ESG score 22.65
Total ESG percentile 18.46
Environmental score 9.35
Environmental score percentile 8
Social score 9.88
Social score percentile 8
Governance score 14.42
Governance score percentile 8
Level of controversy 1

Sinopharm Group Co. shares at a glance

Information last updated 2021-06-28.
Open$2.91
High$2.91
Low$2.91
Close$2.91
Previous close$2.8614
Change$0.0486
Change %1.6985%
Information last updated 2022-09-24.
52-week range$1.92 - $2.7029
50-day moving average$2.1982
200-day moving average$2.2779
PE ratio5.5429
Dividend yield$0 (5.73%)
Earnings per share (TTM)$0.35

Do Sinopharm Group Co. shares pay dividends?

5.7%

Dividend yield: 5.73% of stock value

5.7%

Forward annual dividend yield: 5.73% of stock value

28.1%

Dividend payout ratio: 28.07% of net profits

Sinopharm Group Co. has recently paid out dividends equivalent to 5.73% of its share value annually.

Sinopharm Group Co. has paid out, on average, around 28.07% of recent net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 5.73% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 5.73% return on their shares, in the form of dividend payments. In Sinopharm Group Co.'s case, that would currently equate to about $0 per share.

While Sinopharm Group Co.'s payout ratio might seem fairly standard, it's worth remembering that it may be investing much of the rest of its net profits in future growth.

Sinopharm Group Co.'s most recent dividend payout was on 31 August 2017. The latest dividend was paid out to all shareholders who bought their shares by 27 June 2022 (the "ex-dividend date").

Share price volatility

Over the last 12 months, Sinopharm Group Co.'s shares have ranged in value from as little as $1.92 up to $2.7029. A popular way to gauge a stock's volatility is its "beta".

SHTDF.US volatility(beta: 0.65)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Sinopharm Group Co.'s is 0.6461. This would suggest that Sinopharm Group Co.'s shares are less volatile than average (for this exchange).

Frequently asked questions

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site